tbuckley/cabot-search huggingface dataset:
Raising all boats in supportive oncology: Initial impact of the Coleman Supportive Oncology Collaborative (CSOC).
Authors: Christine B. Weldon, James Gerhart, William Dale, Urjeet Patel, Paramjeet Khosla, Shelly S. Lo, Carol Newsom, Patricia A. Robinson, Eileen Knightly, Rosa Berardi, Aidnag Diaz, Frank J. Penedo, Julia Rachel Trosman
Journal: Journal of Clinical Oncology (2017)

e18205 Background: The Institute of Medicine (IOM) and Commission on Cancer (CoC) recommend systematic delivery of supportive oncology and survivorship care to all cancer patients. CSOC aims to improve the quality of supportive care across Chicago-area providers. Methods: 35 CSOC participating institutions (cancer centers, support centers, hospice) formed care delivery design teams Distress, Survivorship &amp; Palliative. Teams collaboratively developed solutions to supportive oncology gaps: patient screening tools, care delivery processes, provider training, and quality metrics to assess supportive oncology quality and the CSOC impact. Six implementation centers (2 safety-net, 3 academic &amp; 1 public) reviewed charts at baseline (2014 diagnoses) and after the initial implementation period (2015 diagnoses), compared by frequencies and Fisher’s exact test. Results: Eight metrics contained patient data at 2 time points; improvements were seen in 7/8 metrics. Conclusions: CSOC developed supportive oncology screening, and care processes aligned with IOM and CoC standards. Significant improvements were shown after implementation across diverse settings. Ongoing work will further evaluate the impact of CSOC efforts on patient care. [Table: see text]
?Breakthrough? during interferon (IFN) therapy for chronic hepatitis C : Evolution of HCV replication and evaluation of predictive factors . Departments of (1) Bacteriology and Virology, (2) Hepatology and Gastroenterology, (3) Epidemiology, H�pital Henri Mondor, Universit� Paris XII, Cr�teil, and (4) Roche Diagnostics Systems, Neuilly/Seine, France
Journal: Hepatology (1995)
Book Review Fractures and Orthopaedic Surgery for Nurses and Masseuses. By Arthur Naylor, Ch.M., M.B., M.Sc, F.R.C.S. (Eng.), F.R.C.S. (Edin.). With a foreword by Ernest Finch, M.D., M.S. (Lond.), F.R.C.S. (Eng.). 8°, cloth, 288 pp., with 243 illustrations. Baltimore: The Williams and Wilkins Company, 1945. $5.00.
Journal: New England Journal of Medicine (1946)
First-line sunitinib versus pazopanib in metastatic renal cell carcinoma (mRCC): Results from the international metastatic renal cell carcinoma database consortium (IMDC).
Authors: Jose Manuel Ruiz Morales, Marcin Swierkowski, Connor Wells, Anna Paola Fraccon, Francesca La Russa, Frede Donskov, Georg A. Bjarnason, Jae-Lyun Lee, Hao-Wen Sim, Benoit Beuselinck, Lori Wood, Takeshi Yuasa, Carmel Jo Pezaro, Brian I. Rini, Cezary Szczylik, Toni K. Choueiri, Daniel Yick Chin Heng
Journal: Journal of Clinical Oncology (2016)

4510 Background: Sunitinib (SU) and pazopanib (PZ) are standards of care for first-line treatment of metastatic renal cell carcinoma (mRCC). However, how the efficacy of these drugs translates into effectiveness on a population-based level is unknown. Methods: We used the IMDC to assess overall survival (OS), progression-free survival (PFS), response rate (RR) and performed proportional hazard regression adjusting for IMDC prognostic groups. Second-line OS2 and PFS2 were also evaluated. Results: We obtained data from 7438 patients with mRCC treated with either first line SU (n=6519) or PZ (n=919) with an overall median follow-up of 40.4 months (m) (CI95% 39.2 – 42.1). Baseline characteristics are in Table 1. There were no significant differences in IMDC prognostic groups with favorable, intermediate and poor risk patient distributions being 23%, 57%, 20% respectively for sunitinib and 24%, 58%, 18% respectively for pazopanib (p=0.36). There was no OS difference between sunitinib and pazopanib (22.3m vs 22.6m respectively, p=0.65). When adjusted for IMDC criteria, the HR of death for PZ vs SU is 1.03 (95%CI 0.92-1.17, p=0.58). There was no PFS difference between sunitinib and pazopanib (8.4m vs 8.3m respectively, p=0.17). When adjusted for IMDC criteria, the HR for PFS for PZ vs SU 1.08 (95%CI 0.981-1.19, p=0.12). There was no difference in RR between sunitinib and pazopanib (30% vs 28% respectively, p=0.15). We also found no difference in any second-line treatment between either post-SU vs. post-PZ groups for OS2 (12.8m vs. 12.7 m, p=0.91) and PFS2 (3.7 vs. 4.5 m, p=0.50). Conclusions: We confirmed in real-world practice, that SU and PZ have similar efficacy in the first-line setting for mRCC and do not affect outcomes with subsequent second-line treatment. Baseline characteristics at first-line treatment. Characteristic Sunitinib Pazopanib P value Gender M71%/F29% M70%/F30% 0.64 Median Age 62.5 65.3 <0.01 KPS <80% 13% 14% 0.70 Dx to Tx interval<1yr 55% 51% 0.04 Hypercalcemia 13% 13% 0.61 Anemia 45% 44% 0.57 Neutrophilia 13% 12% 0.17 Thrombocytosis 15% 15% 0.77 Prior Nephrectomy 86% 88% 0.09
Listing of presidents of state, regional, and local allergy societies as of January, 1980
Authors: Howard Voss, Edward O'connell, Herman Pinkerton, Robert Ellis, Daniel Goodman, West Camelback, Daisy Lee, Jacob Pinnas, James Kemp, Alan Wanderer, Louis Mendelson, Richard Brams, Samuel Bukantz, Frederick House
Journal: Journal of Allergy and Clinical Immunology (1980)
Fatal retroperitoneal hemorrhage. An unusual complication of renal cortical abscess
Authors: H. W. Murray
Journal: JAMA (1979)

RENAL cortical abscess (renal carbuncle) is an uncommon disorder that may be associated with a variety of clinical and pathological complications. These have included perforation (with or without fistula formation) into contiguous areas such as the peritoneal cavity, perinephric space, and renal pelvis.<sup>1</sup>Peritonitis, perinephric abscess, and urinary tract infection or obstruction may follow. Chronic renal cortical abscess may also closely mimic renal neoplasms and occasionally be responsible for prolonged fever of unknown origin. Recently, we cared for a patient with a renal cortical abscess in whom a massive retroperitoneal hemorrhage developed. Bleeding appeared to result from abscess erosion into the renal vasculature. This case illustrates an unusual and catastrophic complication of a visceral abscess. <h3>Report of a Case</h3> A 42-year-old alcoholic woman was hospitalized because of one day of severe right upper quadrant pain and abrupt abdominal distension. She was acutely ill and tachypneic. The blood pressure was
Nazi Medicine
Journal: JAMA (1998)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Assessment of regional myocardial blood flow and coronary flow reserve using myocardial contrast echocardiography with power pulse imaging: Comparison with neutron activated microsphere Banthit Khankirawatana, Suwanee Khankirawatana, John Lof, Jodie Hallgren-Golka, Thomas R. Porter, Leng Jiang. University of Nebraska Medical Center, Omaha, NE
Journal: Journal of the American College of Cardiology (2001)
Some Effects of Oral Ingestion of Cadmium on Zinc, Copper, and Iron Metabolism
Authors: H. G. Petering, H. Choudhury, K. L. Stemmer
Journal: Environmental Health Perspectives (1979)

Data are presented to show that ingestion of cadmium chloride by rats at low levels leads to alteration of zinc metabolism in the liver, even though the formation of metallothionein is not evident. A dose-response relationship between amount of cadmium ingested and degree of perturbation of zinc metabolism in liver was found. Oral cadmium was shown to cause emphysema and reduce pulmonary function in male rats; the effect was less severe or delayed in onset if dietary zinc concentration was high. Interference with copper and iron metabolism was shown to occur in rats given low levels of cadmium orally. Depression of copper and iron metabolism of the rat fetus was found to occur when dams received very low doses of cadmium during gestation, even though very little cadmium passed the placental barrier.
MEDICAL SERVICES FOR INDUSTRIAL DISASTER
Journal: JAMA (1961)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
International Symposium on Carcinogenesis and Carcinogen Testing
Journal: JNCI Journal of the National Cancer Institute (1967)

International Symposium on Carcinogenesis and Carcinogen Testing Get access JNCI: Journal of the National Cancer Institute, Volume 39, Issue 3, September 1967, Page 585, https://doi.org/10.1093/jnci/39.3.585 Published: 01 September 1967
Résultats de l'enquête SFED 2010 sur la coloscopie: une semaine d'endoscopie en France
Authors: C Boustière, JM Canard, R Laugier, JC Saurin, JP Arpurt, P Bulois, P Burtin, A Calazel, D Heresbach, J Lapuelle, G Lesur, P Pienkowski, T Ponchon, F Prat, B Pujol, B Richard-Molard, R Systchenko, C Cellier
Journal: Endoscopy (2012)

Cette nouvelle enquête de pratique en endoscopie digestive a été réalisée en 2010 pour la première fois sur un mode électronique avec un questionnaire à remplir en ligne. Il a été décidé de ne cibler que les actes les plus fréquents: gastroscopie et coloscopie et de faire cette année un focus sur la coloscopie.
Pedophilia
Authors: Peter J Fagan, Thomas N Wise, Chester W Schmidt, Fred S Berlin
Journal: JAMA (2002)

This article addresses the risk factors associated with the psychiatric disorder pedophilia, its treatment, and treatment outcomes. It addresses physician responsibilities associated with case identification of victims and possible roles in the medical management of pedophilia. The essential feature of pedophilia is that an individual is sexually attracted exclusively or in part to prepubescent children. While pedophilia may be limited to fantasies and impulses, pedophilic behaviors are the primary concern of both the mental health and criminal justice systems. Remote risk factors for development of pedophilia often include the individual having been sexually abused as a child. Proximate risk factors for its behavioral expression are prevalence of comorbid psychiatric disorders and substance abuse disorders. Current treatment goals focus on stopping the behavior and achieving long-term behavioral control in the community. Common treatment methods are cognitive-behavioral, group therapy, and, when appropriate, medications such as androgen-lowering agents that can act as sexual appetite suppressants. Meta-analyses have established that treatment is more effective than nontreatment in preventing recidivism of sexual offenders in general, a finding that has a high probability of application to individuals with pedophilia. Pedophilia is a chronic psychiatric disorder, but it is treatable in terms of developing strategies for preventing behavioral expression. Ultimately, reducing the prevalence of pedophilic behavior requires further collaboration between the criminal justice system and the health care communities.
Erratum
Authors: James R. Gray, James D. Bridges, Mark L. Sobczak
Journal: Journal of Clinical Oncology (1993)

Response Migration: Area Versus Volume for Tumor Response Assessment To the Editor: A correction is necessary regarding the method of assessing tumor response as put forward by Drs Clamon and Clamon. They stated that tumor volume is a stricter criterion than tumor area in determining a partial response (PR, 50% reduction) for use in clinical trials. In fact, just the opposite is true. A PR by measuring tumor area is a more dramatic reduction in tumor bulk than a PR or 50% reduction by measuring tumor volume. Let us demonstrate by example. If a spherical tumor mass originally measures 8 cm across, its initial area calculation is (π)*(r) 2 = 50.26 cm 2 . To be scored as a PR, the area must decrease to 25.13 cm 2 . This corresponds to a mass measuring 5.6 cm across (note, not 4 cm). However, the initial volume of this mass is (4/3)*(π)*(r) = 268.08 cm 3 . To be scored as a PR by the volume criterion the volume must decrease to 134.04 cm 3 . This corresponds to a mass measuring 6.3 cm across. A mere loss of 1.7 cm from the original tumor dimension results in a PR! If area of the tumor is used, the measurement must decrease by 2.4 cm, obviously a more stringent criterion. Trials that require a 50% reduction in tumor area for a PR have in essence demanded a 65% reduction in volume, not a 35% reduction as stated by Clamon and Clamon. If future clinical trials are to use computed tomography or magnetic resonance imaging data to calculate tumor volumes as a measurement of response, and the definition of a PR becomes a 50% reduction in volume, treatment regimens may seemingly become more effective with a higher overall response rate. The corresponding required area reduction in this case would be only 38%, not 50%. Just as more complete staging information can lead to stage migration with fewer malignancies labeled as early stage (the Will Rogers phenomenon 2 ), a change to volume determination for response assessment could lead investigators to conclude erroneously that newer therapies are more successful than those in the past. We must be careful to judge all therapeutic maneuvers on an even playing field to determine truly what is best for our patients.
American Journal of Human Genetics, Baltimore
Journal: JAMA (1966)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Dr. B. Willder's catalogue of Vogue Words
Authors: R. L. Dean
Journal: JAMA (1966)

Here at last is our 1966 Catalogue—truly the biggest and best Spring collection of vogue words for scientists that Solecisms, Unlimited, has ever presented. Order now while these words are still in fashion! Have a full supply on hand for your next staff meeting, or next scientific report. Thousands of Satisfied Users of our Pompous Prose are to be found everywhere—in every hospital, office, laboratory, university, pharmaceutical company, and medical school in the land. To put together this chic collection of Vogue Words, our buyers have searched the country high and low—in the memos of government planners, in the papers of social scientists, in the speeches of politicians. Now, at last, items from the collection are available to all scientists; special discounts by the dozen and the gross. (An abbreviated edition of this catalogue first appeared in the SK&amp;F PSYCHIATRIC REPORTER, May-June, 1965.) <h3>Bizarre—</h3> at its best when misapplied to
Assessment of Trauma in Primary Care
Authors: R. F. Mollica
Journal: JAMA (2001)

Convention Relating to the Status of Refugees-as somebody who, "owing to a well-founded fear of being persecuted for reasons of race, religion, nationality, membership in a particular social group, or political opinion, is outside the country of his nationality, and is unable to or, owing to such fear, is unwilling to avail himself of the protection of that country." 1 Recent estimates suggest that there are approximately 50 million displaced persons worldwide, including internally displaced persons (who have not crossed international borders) and refugees. 2 Health care professionals engage with these populations in numerous ways, ranging from personal, clinical encounters with refugee patients to participation in international medical interventions.Good intentions and sound medical knowledge, however, are not sufficient to provide the health care required by this community of patients.With their history of displacement, persecution, fragmentation of cultural and familial structures, and violation of human rights, displaced persons have a more complicated biopsychosocial profile than most patients in the United States. 3 By becoming more aware of the various issues that affect members of displaced communities, health care providers may become better at confronting their acute and long-term health problems.Furthermore, the health care issues that apply to these populations may also apply to others who do not exactly fit the United Nations definition.Illegal residents or immigrants, those who have been internally displaced, and asylees who do not yet have official refugee status, for example, may benefit from the approaches and perspectives described for refugees.This issue of MS JAMA examines the special problems faced by refugees and displaced persons.Richard Mollica provides a model for how to incorporate the patient's trauma story into the primary care medical interview, so that this essential part of this story is not missed.Health care professionals must take into account the complicated perspectives of culture, human rights, and the ethical problems of international intervention.Stevan Weine proposes a more active engagement with the ramifications of culture in health care interventions, particularly as it pertains to the patient's family and local physicians.Alejandro Moreno and colleagues review the epidemiology of human rights violations in displaced populations and suggest how these might be addressed through the education of physicians and an awareness of human rights violations in the clinical encounter.Gina Jae interviews Philip Gourevitch, the author of We Wish to Inform You That Tomorrow We Will Be Killed With Our Families, a powerful and critical analysis of the genocide and refugee crises in Rwanda in 1994.Ferid Agani examines the mental health system of Kosova after the war and NATO interventions of 1999, focusing on the importance of recognizing local institutions in the rebuilding that goes on after such crises.
Sex Hormone Levels Linked to Breast Cancer Risk in Younger Women
Journal: Cancer Discovery (2013)

Abstract Higher levels of certain sex hormones are shown to be associated with a higher risk of breast cancer in premenopausal women, according to an analysis that pooled seven prospective studies of hormones and breast cancer risk. These increased risks associated with higher concentrations of sex hormones in premenopausal women are smaller but qualitatively similar to those previously reported in postmenopausal women, the researchers say.
Whole genome and transcriptome analysis (WGTA) of metastatic adrenocortical carcinoma (mACC).
Authors: Jean-Michel Lavoie, Veronika Csizmok, Gang Wang, Laura Williamson, Marco A. Marra, Janessa J. Laskin, Steven J. M. Jones, Daniel John Renouf, Christian K. Kollmannsberger
Journal: Journal of Clinical Oncology (2019)

509 Background: mACC is a rare disease, and no standard treatments exist beyond cytotoxic chemotherapy and mitotane. Recurrent molecular changes have been described, but their clinical significance is still poorly understood, and whether they can guide treatment is unknown. Methods: The genomic and transcriptomic profiles of 6 pts with mACC were analyzed as part of a prospective molecular profiling clinical trial. Findings were correlated with histopathological and clinical data. Results: Whole genome sequencing of six ACC tumors and matched normal tissues was performed; whole-transcriptome sequencing was performed on five of the six tumors. All cases met Weiss criteria for ACC (including 1 pt with oncocytic ACC). Profiling revealed gain of function variations in CTNBB1 gene in 3 cases (p.S45A, p.S45P and homozygous deletion of exons 2 and 3). A stop-gained mutation (Q167*) and a homozygous copy loss of TP53 gene was observed in 2 cases; mutations of CTNBB1 and TP53 co-occurred in one case. Variations in other DNA repair genes included BRCA2 E790* stop-gained mutation and a structural variation in RAD52. Copy number amplification was observed for KDM5A (2/6) and RAD52 (2/6), while NF1 (1/6), CDKN2A (1/6), CDKN2B (1/6) and RB1 (2/6) were subjected to homozygous copy losses. Average ploidy models: one diploid, 4 triploid and one tetraploid case; whole chromosome copy losses and gains were seen in all samples. Three cases showed high homologous repair deficiency scores; associated with respectively, an in-frame deletion of V613 in ATM, a TP53 homozygous loss, and a structural variant of RAD52. All six cases exhibit signature 3 or signature 8. At last follow-up, 2 pts remained alive. Treatments included cytotoxic chemotherapy, mitotane, streptozotocin, sunitinib, avelumab with a SMAC mimetic, a TTK inhibitor on the basis of a CTNNB1 mutation, and temozolomide with olaparib on the basis of ATM loss. Conclusions: Our findings recapitulate published data on the molecular profile of mACC and support previous findings of large scale chromosomal variation. We identify new potential drivers in chromatin remodelling, cell cycle, and DNA damage repair genes. (NCT02155621, NCT02022098, NCT02792465).